VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Citius Pharmaceuticals, Inc. (CTXR) Total Return Calculator with Dividends Reinvested

Citius Pharmaceuticals, Inc.

Popular:

The total return for Citius Pharmaceuticals, Inc. (CTXR) stock is -8.40% over the past 12 months. So far it's down 21.42% this year. The 5-year total return is -98.78%, meaning $10,000 invested in CTXR stock 5 years ago would be worth $122 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in CTXR 1 year ago, it would be worth $9,561 today — you'd have lost $439.

With Dividends Reinvested$9,561-4.39%

Price Only (No DRIP)$9,561-4.39%

Period2025-05-07 → 2026-05-06

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in CTXR

1Y$9,160-$840 (-8.4%)-8.4% CAGR

3Y$208-$9,792 (-97.9%)-72.5% CAGR

5Y$122-$9,878 (-98.8%)-58.6% CAGR

10Y$13-$9,987 (-99.9%)-48.7% CAGR

15Y$18-$9,982 (-99.8%)-34.4% CAGR

20Y$18-$9,982 (-99.8%)-27.1% CAGR

30Y$18-$9,982 (-99.8%)-19.0% CAGR

Citius Pharmaceuticals, Inc. did not pay dividends during this period. Total return = price return.

Loading CTXR total return...

As of 2026-05-07

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-21.42%	—	-21.42%	—	$7,858
1Y	-8.40%	-8.40%	-8.40%	—	$9,160
3Y	-97.92%	-72.49%	-97.92%	—	$208
5Y	-98.78%	-58.56%	-98.78%	—	$122
10Y	-99.87%	-48.67%	-99.87%	—	$13
15Y	-99.82%	-34.44%	-99.82%	—	$18
20Y	-99.82%	-27.14%	-99.82%	—	$18
30Y	-99.82%	-19.03%	-99.82%	—	$18

Risk & Highlights

Best Year+77.88%2015

Worst Year-80.22%2024

Max Drawdown-73.07%2025-07-03 → 2026-04-29

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-12.74%	-12.74%	—	+0.41%	-13.1pp
2025	-79.97%	-79.97%	—	+16.64%	-96.6pp
2024	-80.22%	-80.22%	—	+24.00%	-104.2pp
2023	-3.03%	-3.03%	—	+24.81%	-27.8pp
2022	-52.69%	-52.69%	—	-19.95%	-32.7pp

CTXR underperformed the S&P 500 by 39.72pp over the past year (-8.40% vs +31.32%).

Loading summary...

CTXR Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
CTXRCitius Pharmaceuticals, Inc.	$12M	-22.5%	-21.4%	-8.4%	—	-97.9%	-98.8%	-99.9%
NKTRNektar Therapeutics	$1.7B	+13.9%	+96.0%	+783.6%	—	+636.7%	-69.4%	-57.6%
HALOHalozyme Therapeutics, Inc.	$7.8B	+5.2%	-5.6%	+11.7%	—	+119.1%	+39.1%	+598.4%
PRGOPerrigo Company plc	$1.7B	+15.8%	-9.6%	-45.6%	+4.7pp	-56.6%	-58.6%	-76.8%
PAHCPhibro Animal Health Corporation	$2.4B	+6.7%	+57.5%	+210.5%	+2.5pp	+318.1%	+136.4%	+207.3%
ETONEton Pharmaceuticals, Inc.	$815M	+20.6%	+85.4%	+81.3%	—	+768.9%	+272.7%	+382.4%
TLRYTilray Brands, Inc.	$671M	-13.5%	-40.7%	+1268.2%	—	+107.2%	-59.3%	-74.3%
MNKDMannKind Corporation	$1.1B	+39.1%	-36.4%	-25.5%	—	-8.2%	-12.7%	-46.5%
ACRSAclaris Therapeutics, Inc.	$576M	+25.8%	+66.0%	+273.4%	—	-43.1%	-79.9%	-76.9%
PHATPhathom Pharmaceuticals, Inc.	$1.0B	+12.6%	-19.4%	+427.9%	—	+2.7%	-62.3%	-48.5%
MCKMcKesson Corporation	$91.1B	-13.2%	-9.6%	+5.0%	+0.4pp	+104.0%	+308.4%	+351.9%

Compare:CTXR vs NKTR CTXR vs HALO CTXR vs PRGO CTXR vs NKTR vs HALO

About CTXR Dividend Returns

Citius Pharmaceuticals, Inc. (CTXR) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of CTXR over the past year?

Citius Pharmaceuticals, Inc. (CTXR) delivered a return of -8.40% over the past year. Since CTXR does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in CTXR be worth today?

A $10,000 investment in Citius Pharmaceuticals, Inc. one year ago would be worth $9,160 today, representing a loss of $840.

Q3Does CTXR pay dividends?

Citius Pharmaceuticals, Inc. (CTXR) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For CTXR, the total return equals the price-only return.

Q4Did CTXR beat the S&P 500?

No, Citius Pharmaceuticals, Inc. (CTXR) underperformed the S&P 500 by 39.72 percentage points over the past year. CTXR delivered a total return of -8.40%, compared to the S&P 500's 31.32%. This means a passive S&P 500 index fund outperformed CTXR by 39.72pp during this period.

Q5What is CTXR's worst drawdown?

Citius Pharmaceuticals, Inc. (CTXR) experienced a maximum drawdown of -73.07% over the past year, declining from its peak on 2025-07-03 to its trough on 2026-04-29. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is CTXR's long-term total return over 10, 20, or 30 years?

Here are Citius Pharmaceuticals, Inc. (CTXR)'s long-term returns with dividends reinvested. Over 10 years, the total return is -99.9% (-48.7% CAGR) — $10,000 would have grown to $13. Over 20 years: -99.8% total return (-27.1% CAGR) — $10,000 → $18. Over 30 years: -99.8% total return (-19.0% CAGR) — $10,000 → $18. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was CTXR's best and worst year?

Citius Pharmaceuticals, Inc.'s best calendar year was 2015 with a total return of 77.9%. Its worst year was 2024 with a total return of -80.2%. This range shows the volatility investors should expect — the difference between the best and worst year is 158.1 percentage points.